Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-07-15

AUTHORS

Omid Hamid, Brianna Hoffner, Eduard Gasal, Jenny Hong, Richard D. Carvajal

ABSTRACT

Oncolytic immunotherapy is a research area of cancer immunotherapy investigating the use of modified viruses to target cancer cells. A variety of different viral backbones (e.g., adenovirus, reovirus) with a diverse range of genetic modifications are currently being investigated for the treatment of a variety of cancers. The oncolytic virus that has advanced the furthest in clinical development is talimogene laherparepvec, a recombinant HSV-1 virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF). In a phase 3 study in patients with unresectable metastatic melanoma, intralesional talimogene laherparepvec treatment resulted in a higher durable response rate compared with subcutaneous GM-CSF treatment (16.3 versus 2.1%; P < 0.001). Notably, responses were observed at uninjected lesions including visceral lesions, indicating a systemic antitumor response had occurred. Studies evaluating combination treatments involving oncolytic viruses and immunologic agents are ongoing. This review focuses on the mechanisms of action for oncolytic viruses and highlights select agents and combinations currently in development. More... »

PAGES

1249-1264

References to SciGraph publications

  • 2016-03-15. Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2009-11-14. Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma in ANNALS OF SURGICAL ONCOLOGY
  • 2001-11-01. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial in GENE THERAPY
  • 2007-02. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2005-01-13. Phase I–II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas in GENE THERAPY
  • 2003-04-29. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients in CANCER GENE THERAPY
  • 2011-11-10. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4 in GENE THERAPY
  • 2016-06-24. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial in ANNALS OF SURGICAL ONCOLOGY
  • 2003-05-19. GM-CSF-secreting melanoma vaccines in ONCOGENE
  • 2004-10-08. Replication-selective oncolytic viruses in the treatment of cancer in CANCER GENE THERAPY
  • 2012-08-12. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors in INVESTIGATIONAL NEW DRUGS
  • 2003-02-01. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties in GENE THERAPY
  • 2013-02-10. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer in NATURE MEDICINE
  • 2000-08. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer in NATURE MEDICINE
  • 2014-11-06. Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704) in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2001-07. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions in NATURE MEDICINE
  • 2008-02-07. Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21 in BREAST CANCER RESEARCH AND TREATMENT
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00262-017-2025-8

    DOI

    http://dx.doi.org/10.1007/s00262-017-2025-8

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1090688769

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/28712033


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunotherapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Melanoma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Oncolytic Virotherapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Oncolytic Viruses", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "The Angeles Clinic and Research Institute, 11818 Wilshire Blvd #200, 90025, Los Angeles, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.488730.0", 
              "name": [
                "The Angeles Clinic and Research Institute, 11818 Wilshire Blvd #200, 90025, Los Angeles, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hamid", 
            "givenName": "Omid", 
            "id": "sg:person.0575703507.41", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0575703507.41"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University of Colorado Hospital, Aurora, CO, USA", 
              "id": "http://www.grid.ac/institutes/grid.413085.b", 
              "name": [
                "University of Colorado Hospital, Aurora, CO, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hoffner", 
            "givenName": "Brianna", 
            "id": "sg:person.01364736503.34", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364736503.34"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Amgen Inc., Thousand Oaks, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.417886.4", 
              "name": [
                "Amgen Inc., Thousand Oaks, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gasal", 
            "givenName": "Eduard", 
            "id": "sg:person.015042767114.05", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015042767114.05"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cedars-Sinai Medical Center, Los Angeles, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.50956.3f", 
              "name": [
                "Cedars-Sinai Medical Center, Los Angeles, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hong", 
            "givenName": "Jenny", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Columbia University Medical Center, New York, NY, USA", 
              "id": "http://www.grid.ac/institutes/grid.239585.0", 
              "name": [
                "Columbia University Medical Center, New York, NY, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Carvajal", 
            "givenName": "Richard D.", 
            "id": "sg:person.0726366600.25", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s10549-008-9899-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006378409", 
              "https://doi.org/10.1007/s10549-008-9899-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.gt.3301885", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014089334", 
              "https://doi.org/10.1038/sj.gt.3301885"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/gt.2011.176", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039251497", 
              "https://doi.org/10.1038/gt.2011.176"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.gt.3301512", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052301768", 
              "https://doi.org/10.1038/sj.gt.3301512"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.gt.3302436", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022292061", 
              "https://doi.org/10.1038/sj.gt.3302436"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm.3089", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031223927", 
              "https://doi.org/10.1038/nm.3089"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1206459", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017146287", 
              "https://doi.org/10.1038/sj.onc.1206459"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10637-012-9865-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010325857", 
              "https://doi.org/10.1007/s10637-012-9865-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ncponc0736", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021336582", 
              "https://doi.org/10.1038/ncponc0736"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/2051-1426-2-s3-p263", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042181601", 
              "https://doi.org/10.1186/2051-1426-2-s3-p263"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1245/s10434-009-0809-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003516195", 
              "https://doi.org/10.1245/s10434-009-0809-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.cgt.7700771", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006065171", 
              "https://doi.org/10.1038/sj.cgt.7700771"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s40425-016-0121-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031122156", 
              "https://doi.org/10.1186/s40425-016-0121-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.cgt.7700585", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003963695", 
              "https://doi.org/10.1038/sj.cgt.7700585"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/78638", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009134605", 
              "https://doi.org/10.1038/78638"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/89901", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014409607", 
              "https://doi.org/10.1038/89901"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1245/s10434-016-5286-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030274198", 
              "https://doi.org/10.1245/s10434-016-5286-0"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2017-07-15", 
        "datePublishedReg": "2017-07-15", 
        "description": "Oncolytic immunotherapy is a research area of cancer immunotherapy investigating the use of modified viruses to target cancer cells. A variety of different viral backbones (e.g., adenovirus, reovirus) with a diverse range of genetic modifications are currently being investigated for the treatment of a variety of cancers. The oncolytic virus that has advanced the furthest in clinical development is talimogene laherparepvec, a recombinant HSV-1 virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF). In a phase 3 study in patients with unresectable metastatic melanoma, intralesional talimogene laherparepvec treatment resulted in a higher durable response rate compared with subcutaneous GM-CSF treatment (16.3 versus 2.1%; P\u00a0<\u00a00.001). Notably, responses were observed at uninjected lesions including visceral lesions, indicating a systemic antitumor response had occurred. Studies evaluating combination treatments involving oncolytic viruses and immunologic agents are ongoing. This review focuses on the mechanisms of action for oncolytic viruses and highlights select agents and combinations currently in development.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00262-017-2025-8", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1096240", 
            "issn": [
              "0340-7004", 
              "1432-0851"
            ], 
            "name": "Cancer Immunology, Immunotherapy", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "10", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "66"
          }
        ], 
        "keywords": [
          "oncolytic viruses", 
          "durable response rate", 
          "phase 3 study", 
          "systemic antitumor response", 
          "recombinant HSV-1 virus", 
          "unresectable metastatic melanoma", 
          "granulocyte-macrophage colony-stimulating factor", 
          "GM-CSF treatment", 
          "colony-stimulating factor", 
          "variety of cancers", 
          "HSV-1 virus", 
          "mechanism of action", 
          "uninjected lesions", 
          "oncolytic immunotherapy", 
          "talimogene laherparepvec", 
          "visceral lesions", 
          "antitumor response", 
          "immunologic agents", 
          "cancer immunotherapy", 
          "metastatic melanoma", 
          "combination treatment", 
          "clinical development", 
          "response rate", 
          "cancer cells", 
          "virus", 
          "immunotherapy", 
          "treatment", 
          "lesions", 
          "cancer", 
          "viral backbone", 
          "potential of viruses", 
          "laherparepvec", 
          "patients", 
          "melanoma", 
          "agents", 
          "response", 
          "study", 
          "cells", 
          "genetic modification", 
          "review", 
          "factors", 
          "development", 
          "action", 
          "rate", 
          "variety", 
          "mechanism", 
          "diverse range", 
          "use", 
          "combination", 
          "potential", 
          "area", 
          "highlights", 
          "modification", 
          "range", 
          "research area", 
          "backbone"
        ], 
        "name": "Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer", 
        "pagination": "1249-1264", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1090688769"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00262-017-2025-8"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "28712033"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00262-017-2025-8", 
          "https://app.dimensions.ai/details/publication/pub.1090688769"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:36", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_726.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00262-017-2025-8"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00262-017-2025-8'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00262-017-2025-8'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00262-017-2025-8'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00262-017-2025-8'


     

    This table displays all metadata directly associated to this object as RDF triples.

    244 TRIPLES      21 PREDICATES      103 URIs      78 LITERALS      12 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00262-017-2025-8 schema:about N132a5d8c362840b8af7fab44100710ef
    2 N89f9a8a2886945eab565f823615c7f4e
    3 Na03837877b2f4e8faeb30835ac5995c5
    4 Na87b72e3b9154b649a8985984c73b52e
    5 Nc6e6928be1664bc9b81db3f3472b4c2f
    6 anzsrc-for:11
    7 anzsrc-for:1107
    8 schema:author N0fdbf4a073644721bcc1ed812398c3f2
    9 schema:citation sg:pub.10.1007/s10549-008-9899-2
    10 sg:pub.10.1007/s10637-012-9865-z
    11 sg:pub.10.1038/78638
    12 sg:pub.10.1038/89901
    13 sg:pub.10.1038/gt.2011.176
    14 sg:pub.10.1038/ncponc0736
    15 sg:pub.10.1038/nm.3089
    16 sg:pub.10.1038/sj.cgt.7700585
    17 sg:pub.10.1038/sj.cgt.7700771
    18 sg:pub.10.1038/sj.gt.3301512
    19 sg:pub.10.1038/sj.gt.3301885
    20 sg:pub.10.1038/sj.gt.3302436
    21 sg:pub.10.1038/sj.onc.1206459
    22 sg:pub.10.1186/2051-1426-2-s3-p263
    23 sg:pub.10.1186/s40425-016-0121-5
    24 sg:pub.10.1245/s10434-009-0809-6
    25 sg:pub.10.1245/s10434-016-5286-0
    26 schema:datePublished 2017-07-15
    27 schema:datePublishedReg 2017-07-15
    28 schema:description Oncolytic immunotherapy is a research area of cancer immunotherapy investigating the use of modified viruses to target cancer cells. A variety of different viral backbones (e.g., adenovirus, reovirus) with a diverse range of genetic modifications are currently being investigated for the treatment of a variety of cancers. The oncolytic virus that has advanced the furthest in clinical development is talimogene laherparepvec, a recombinant HSV-1 virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF). In a phase 3 study in patients with unresectable metastatic melanoma, intralesional talimogene laherparepvec treatment resulted in a higher durable response rate compared with subcutaneous GM-CSF treatment (16.3 versus 2.1%; P < 0.001). Notably, responses were observed at uninjected lesions including visceral lesions, indicating a systemic antitumor response had occurred. Studies evaluating combination treatments involving oncolytic viruses and immunologic agents are ongoing. This review focuses on the mechanisms of action for oncolytic viruses and highlights select agents and combinations currently in development.
    29 schema:genre article
    30 schema:isAccessibleForFree true
    31 schema:isPartOf N02ca1f9a49b5424cbe3805844b8184cf
    32 N129ebe99f5414ba5a7e43260d147159f
    33 sg:journal.1096240
    34 schema:keywords GM-CSF treatment
    35 HSV-1 virus
    36 action
    37 agents
    38 antitumor response
    39 area
    40 backbone
    41 cancer
    42 cancer cells
    43 cancer immunotherapy
    44 cells
    45 clinical development
    46 colony-stimulating factor
    47 combination
    48 combination treatment
    49 development
    50 diverse range
    51 durable response rate
    52 factors
    53 genetic modification
    54 granulocyte-macrophage colony-stimulating factor
    55 highlights
    56 immunologic agents
    57 immunotherapy
    58 laherparepvec
    59 lesions
    60 mechanism
    61 mechanism of action
    62 melanoma
    63 metastatic melanoma
    64 modification
    65 oncolytic immunotherapy
    66 oncolytic viruses
    67 patients
    68 phase 3 study
    69 potential
    70 potential of viruses
    71 range
    72 rate
    73 recombinant HSV-1 virus
    74 research area
    75 response
    76 response rate
    77 review
    78 study
    79 systemic antitumor response
    80 talimogene laherparepvec
    81 treatment
    82 uninjected lesions
    83 unresectable metastatic melanoma
    84 use
    85 variety
    86 variety of cancers
    87 viral backbone
    88 virus
    89 visceral lesions
    90 schema:name Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer
    91 schema:pagination 1249-1264
    92 schema:productId N15f20717cd4a43d6b9709484cc9e7cef
    93 N817840564cab42aaaf99a5cab0ac4af1
    94 Nfd95c50a2f4a4da08ddd03fe3109d72e
    95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090688769
    96 https://doi.org/10.1007/s00262-017-2025-8
    97 schema:sdDatePublished 2022-12-01T06:36
    98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    99 schema:sdPublisher N03550f727c4f490e96c06b7b8064da73
    100 schema:url https://doi.org/10.1007/s00262-017-2025-8
    101 sgo:license sg:explorer/license/
    102 sgo:sdDataset articles
    103 rdf:type schema:ScholarlyArticle
    104 N02ca1f9a49b5424cbe3805844b8184cf schema:issueNumber 10
    105 rdf:type schema:PublicationIssue
    106 N03550f727c4f490e96c06b7b8064da73 schema:name Springer Nature - SN SciGraph project
    107 rdf:type schema:Organization
    108 N064e0fe757014c06826f30f9a685145e schema:affiliation grid-institutes:grid.50956.3f
    109 schema:familyName Hong
    110 schema:givenName Jenny
    111 rdf:type schema:Person
    112 N0fdbf4a073644721bcc1ed812398c3f2 rdf:first sg:person.0575703507.41
    113 rdf:rest N2bfdb080e61c4a269e81f2f54b4385f3
    114 N129ebe99f5414ba5a7e43260d147159f schema:volumeNumber 66
    115 rdf:type schema:PublicationVolume
    116 N132a5d8c362840b8af7fab44100710ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    117 schema:name Oncolytic Viruses
    118 rdf:type schema:DefinedTerm
    119 N15f20717cd4a43d6b9709484cc9e7cef schema:name dimensions_id
    120 schema:value pub.1090688769
    121 rdf:type schema:PropertyValue
    122 N2b939ed5cc0f49c4b68e7856dbe7c52e rdf:first sg:person.015042767114.05
    123 rdf:rest N9cf247534fc6444998e465f8c45b8d7e
    124 N2bfdb080e61c4a269e81f2f54b4385f3 rdf:first sg:person.01364736503.34
    125 rdf:rest N2b939ed5cc0f49c4b68e7856dbe7c52e
    126 N7a9fec70f74e4771ae125eb65d0824e0 rdf:first sg:person.0726366600.25
    127 rdf:rest rdf:nil
    128 N817840564cab42aaaf99a5cab0ac4af1 schema:name pubmed_id
    129 schema:value 28712033
    130 rdf:type schema:PropertyValue
    131 N89f9a8a2886945eab565f823615c7f4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Immunotherapy
    133 rdf:type schema:DefinedTerm
    134 N9cf247534fc6444998e465f8c45b8d7e rdf:first N064e0fe757014c06826f30f9a685145e
    135 rdf:rest N7a9fec70f74e4771ae125eb65d0824e0
    136 Na03837877b2f4e8faeb30835ac5995c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    137 schema:name Melanoma
    138 rdf:type schema:DefinedTerm
    139 Na87b72e3b9154b649a8985984c73b52e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    140 schema:name Oncolytic Virotherapy
    141 rdf:type schema:DefinedTerm
    142 Nc6e6928be1664bc9b81db3f3472b4c2f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    143 schema:name Humans
    144 rdf:type schema:DefinedTerm
    145 Nfd95c50a2f4a4da08ddd03fe3109d72e schema:name doi
    146 schema:value 10.1007/s00262-017-2025-8
    147 rdf:type schema:PropertyValue
    148 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    149 schema:name Medical and Health Sciences
    150 rdf:type schema:DefinedTerm
    151 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
    152 schema:name Immunology
    153 rdf:type schema:DefinedTerm
    154 sg:journal.1096240 schema:issn 0340-7004
    155 1432-0851
    156 schema:name Cancer Immunology, Immunotherapy
    157 schema:publisher Springer Nature
    158 rdf:type schema:Periodical
    159 sg:person.01364736503.34 schema:affiliation grid-institutes:grid.413085.b
    160 schema:familyName Hoffner
    161 schema:givenName Brianna
    162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364736503.34
    163 rdf:type schema:Person
    164 sg:person.015042767114.05 schema:affiliation grid-institutes:grid.417886.4
    165 schema:familyName Gasal
    166 schema:givenName Eduard
    167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015042767114.05
    168 rdf:type schema:Person
    169 sg:person.0575703507.41 schema:affiliation grid-institutes:grid.488730.0
    170 schema:familyName Hamid
    171 schema:givenName Omid
    172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0575703507.41
    173 rdf:type schema:Person
    174 sg:person.0726366600.25 schema:affiliation grid-institutes:grid.239585.0
    175 schema:familyName Carvajal
    176 schema:givenName Richard D.
    177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25
    178 rdf:type schema:Person
    179 sg:pub.10.1007/s10549-008-9899-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006378409
    180 https://doi.org/10.1007/s10549-008-9899-2
    181 rdf:type schema:CreativeWork
    182 sg:pub.10.1007/s10637-012-9865-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1010325857
    183 https://doi.org/10.1007/s10637-012-9865-z
    184 rdf:type schema:CreativeWork
    185 sg:pub.10.1038/78638 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009134605
    186 https://doi.org/10.1038/78638
    187 rdf:type schema:CreativeWork
    188 sg:pub.10.1038/89901 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014409607
    189 https://doi.org/10.1038/89901
    190 rdf:type schema:CreativeWork
    191 sg:pub.10.1038/gt.2011.176 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039251497
    192 https://doi.org/10.1038/gt.2011.176
    193 rdf:type schema:CreativeWork
    194 sg:pub.10.1038/ncponc0736 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021336582
    195 https://doi.org/10.1038/ncponc0736
    196 rdf:type schema:CreativeWork
    197 sg:pub.10.1038/nm.3089 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031223927
    198 https://doi.org/10.1038/nm.3089
    199 rdf:type schema:CreativeWork
    200 sg:pub.10.1038/sj.cgt.7700585 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003963695
    201 https://doi.org/10.1038/sj.cgt.7700585
    202 rdf:type schema:CreativeWork
    203 sg:pub.10.1038/sj.cgt.7700771 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006065171
    204 https://doi.org/10.1038/sj.cgt.7700771
    205 rdf:type schema:CreativeWork
    206 sg:pub.10.1038/sj.gt.3301512 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052301768
    207 https://doi.org/10.1038/sj.gt.3301512
    208 rdf:type schema:CreativeWork
    209 sg:pub.10.1038/sj.gt.3301885 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014089334
    210 https://doi.org/10.1038/sj.gt.3301885
    211 rdf:type schema:CreativeWork
    212 sg:pub.10.1038/sj.gt.3302436 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022292061
    213 https://doi.org/10.1038/sj.gt.3302436
    214 rdf:type schema:CreativeWork
    215 sg:pub.10.1038/sj.onc.1206459 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017146287
    216 https://doi.org/10.1038/sj.onc.1206459
    217 rdf:type schema:CreativeWork
    218 sg:pub.10.1186/2051-1426-2-s3-p263 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042181601
    219 https://doi.org/10.1186/2051-1426-2-s3-p263
    220 rdf:type schema:CreativeWork
    221 sg:pub.10.1186/s40425-016-0121-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031122156
    222 https://doi.org/10.1186/s40425-016-0121-5
    223 rdf:type schema:CreativeWork
    224 sg:pub.10.1245/s10434-009-0809-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003516195
    225 https://doi.org/10.1245/s10434-009-0809-6
    226 rdf:type schema:CreativeWork
    227 sg:pub.10.1245/s10434-016-5286-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030274198
    228 https://doi.org/10.1245/s10434-016-5286-0
    229 rdf:type schema:CreativeWork
    230 grid-institutes:grid.239585.0 schema:alternateName Columbia University Medical Center, New York, NY, USA
    231 schema:name Columbia University Medical Center, New York, NY, USA
    232 rdf:type schema:Organization
    233 grid-institutes:grid.413085.b schema:alternateName University of Colorado Hospital, Aurora, CO, USA
    234 schema:name University of Colorado Hospital, Aurora, CO, USA
    235 rdf:type schema:Organization
    236 grid-institutes:grid.417886.4 schema:alternateName Amgen Inc., Thousand Oaks, CA, USA
    237 schema:name Amgen Inc., Thousand Oaks, CA, USA
    238 rdf:type schema:Organization
    239 grid-institutes:grid.488730.0 schema:alternateName The Angeles Clinic and Research Institute, 11818 Wilshire Blvd #200, 90025, Los Angeles, CA, USA
    240 schema:name The Angeles Clinic and Research Institute, 11818 Wilshire Blvd #200, 90025, Los Angeles, CA, USA
    241 rdf:type schema:Organization
    242 grid-institutes:grid.50956.3f schema:alternateName Cedars-Sinai Medical Center, Los Angeles, CA, USA
    243 schema:name Cedars-Sinai Medical Center, Los Angeles, CA, USA
    244 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...